Radioactive drug targets Hard-to-Treat eye cancer in first human trial
NCT ID NCT05496686
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial tests a radioactive drug called 225Ac-MTI-201 in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the safest dose and understand side effects. Only 16 participants will receive a single IV dose, with doses increasing in small groups to determine the maximum tolerated dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
225Ac-MTI-201 (a radioactive drug given by IV)
What this could lead to
If it works, this could point toward a new treatment option for metastatic uveal melanoma, a rare eye cancer that has spread.
What could go wrong
This is a very early, small Phase 1 trial with only 16 people. The main goal is to find a safe dose, not to prove it works. Radioactive drugs can cause serious side effects like low blood counts or liver injury.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.